腫脹膝蓋治療市場規模、佔有率和成長分析：按類型、最終用戶和地區分類 - 行業預測，2024-2031 年

腫脹膝蓋治療市場規模將於 2022 年達到 20 億美元，從 2023 年的 20.9 億美元成長到 2031 年的 29.7 億美元，預測期（2024-2031）預計將以 4.5% 的複合年成長率成長。

由於向非手術醫療保健的顯著轉變，腫脹的膝蓋治療市場可能會在其成長軌跡中遇到障礙。這一趨勢反映出人們普遍偏好微創和非侵入性治療，相對於傳統手術更青睞治療方式。人們越來越意識到與膝關節置換術等手術相關的潛在風險和併發症，這有助於患者偏好的改變。人們擴大尋求具有可比功效的替代品，同時降低風險並縮短恢復時間。

目錄

介紹

• 這項研究的目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 價值鏈分析
• 價格分析
• Start-Ups分析
• 監管環境
• 專利分析
• 管道分析
• 關鍵成功因素
• 市場吸引力指數
• 競爭程度
• 關鍵投資機會
• 生態系繪圖

腫脹的膝蓋治療市場：按類型

• 市場概況
• 藥品
• 病人自控鎮痛泵
• 神經阻斷
• 布比卡因Bupivacaine
• 外科手術

膝蓋腫脹治療市場：依醫藥產品分類

• 市場概況
• 鴉片類藥物
• 皮質類固醇
• 其他

膝蓋腫脹治療市場：透過手術

• 市場概況
• 關節穿刺術
• 關節鏡
• 關節重建置換術
  • 全膝關節置換術
  • 單間室膝關節關節重建
  • 其他

腫脹的膝蓋治療市場：按最終用戶分類

• 市場概況
• 醫院
• 指定診所
• 門診手術中心
• 其他

按地區分類的膝蓋腫脹治療市場規模

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Pfizer Inc.（United States）
• Johnson & Johnson（United States）
• Novartis AG（Switzerland）
• GlaxoSmithKline plc（United Kingdom）
• Merck & Co., Inc.（United States）
• Bayer AG（Germany）
• Sanofi（France）
• Eli Lilly and Company（United States）
• Abbott Laboratories（United States）
• AstraZeneca plc（United Kingdom）
• Bristol-Myers Squibb Company（United States）
• Boehringer Ingelheim GmbH（Germany）
• AbbVie Inc.（United States）
• Amgen Inc.（United States）
• F. Hoffmann-La Roche AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Mylan NV（United States）
• Novo Nordisk A/S（Denmark）
• Allergan plc（United States）
• Takeda Pharmaceutical Company Limited（Japan）

Swollen Knee Treatment Market size was valued at USD 2.00 billion in 2022 and is poised to grow from USD 2.09 billion in 2023 to USD 2.97 billion by 2031, growing at a CAGR of 4.5% in the forecast period (2024-2031).

The swollen knee treatment market might encounter obstacles in its growth path due to a noticeable shift towards non-surgical healthcare options. This trend advocates for healing modalities over traditional surgery, reflecting a broader preference for less invasive and non-invasive treatments. Heightened awareness of potential risks and complications linked to procedures like knee arthroplasty contributes to this change in patient preferences. People are increasingly seeking alternatives that offer comparable efficacy with reduced risks and shorter recovery periods.

Top-down and bottom-up approaches were used to estimate and validate the size of the Swollen Knee Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Swollen Knee Treatment Market Segmental Analysis

The swollen knee treatment market is segmented based on type, end user, and region. Based on type, the market is segmented into Medications (Opioids, Corticosteroids, Others), Patient-controlled Analgesia Pumps, Nerve Blocks, Liposomal Bupivacaine, Surgery (Arthrocentesis, Arthroscopy, Knee Replacement). Based on end user, the market is segmented into hospitals, designated clinics, ambulatory surgical centers, and others. Based on region, the swollen knee treatment market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

Drivers of the Swollen Knee Treatment Market

The escalating healthcare expenses in the market create substantial prospects for enhancing accessibility, innovation, and efficiency within the dental care industry. Improved income distribution enables better healthcare services, cutting-edge technology, and enhanced medical treatments. However, to fully capitalize on these opportunities, it is crucial to tackle challenges such as uneven distribution, ethical considerations, and financial viability. Implementing appropriate and well-planned sustainability measures is essential to ensure that increased healthcare expenditure benefits all segments of the population, thereby reducing disparities in access to dental care.

Restraints in the Swollen Knee Treatment Market

Advanced medical procedures like knee replacement surgery often pose financial obstacles that restrict access for patients with limited resources. The expenses related to knee replacement surgery encompass various elements such as preoperative assessments, surgical techniques, postoperative care, and rehabilitation, making access to this beneficial treatment limited. The financial challenges associated with advanced procedures like knee replacement surgery highlight the significance of addressing healthcare disparities and ensuring equitable access to treatment for all.

Market Trends of the Swollen Knee Treatment Market

Ongoing advancements in medical device technology, particularly in knee-related solutions, offer significant opportunities for innovative therapeutic approaches to tackle orthopedic conditions. Innovations in knee braces and assistive devices mark a new era in medical solutions, enhancing patient comfort and optimizing treatment outcomes. These modern devices are engineered to deliver precise, stable, and reliable support for a spectrum of knee-related issues, spanning from injuries to chronic conditions. This evolution supports healthcare professionals in tailoring interventions according to the unique needs of each patient, thereby advancing personalized treatment options.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Pricing Analysis
• Start Up Analysis
• Regulatory Landscape
• Patent Analysis
• Pipeline Analysis
• Key Success Factors
• Market Attractiveness Index
• Degree of Competition
• Top Investment Pockets
• Ecosystem Mapping

Swollen Knee Treatment Market by Type

• Market Overview
• Medications
• Patient-controlled Analgesia Pumps
• Nerve Blocks
• Liposomal Bupivacaine
• Surgery

Swollen Knee Treatment Market by Medications

• Market Overview
• Opioids
• Corticosteroids
• Others

Swollen Knee Treatment Market by Surgery

• Market Overview
• Arthrocentesis
• Arthroscopy
• Knee Replacement
  • Total Knee Replacement
  • Unicompartmental Knee Replacement
  • Others

Swollen Knee Treatment Market by End User

• Market Overview
• Hospitals
• Designated Clinics
• Ambulatory Surgical Centers
• Others

Swollen Knee Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments